New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:02 EDTISIS, BIIBIsis receives $14M payment from Biogen with Phase 1 initiation
Isis Pharmaceuticals (ISIS) announced that it has initiated a Phase 1 study for ISIS-DMPK. Isis earned a $14M milestone payment from Biogen Idec (BIIB) associated with this achievement. ISIS-DMPK is designed to reduce the production of toxic dystrophia myotonica-protein kinase RNA in cells, including muscle cells, for the treatment of Myotonic Dystrophy Type.
News For ISIS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
07:37 EDTISISIsis Pharmaceuticals management to meet with Deutsche Bank
Subscribe for More Information
September 29, 2014
08:25 EDTISISIsis Pharmaceuticals management to meet with Deutsche Bank
Meetings to be held in Baltimore/Philadelphia on September 29 hosted by Deutsche Bank.
07:26 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
September 26, 2014
10:01 EDTISISOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:20 EDTISISIsis Pharmaceuticals assumed with a Market Perform at Leerink
Subscribe for More Information
September 25, 2014
08:59 EDTISISSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
September 22, 2014
15:14 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Meeting to be held in Los Angeles on September 22 hosted by JPMorgan.
07:21 EDTBIIBEBD Group to hold a conference
Subscribe for More Information
September 17, 2014
07:29 EDTISISIsis Pharmaceuticals earns $4M from Achaogen for Phase 3 study of plazomicin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use